Abstracts tagged "Patient reported outcomes"

Abstract Number: 1320 • ACR Convergence 2024
Acceptability and Satisfaction of an Online Resilience-Building Intervention with Peer Health Coaches for Managing Fatigue and Well-Being in Systemic Sclerosis
Susan Murphy¹, Yen Chen², Alexandra Harper², Nirali Shah², Mary Alore², Sheri Hicks², Adam Pape³ and Dinesh Khanna², ¹University of Michigan, Plymouth, MI, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, University of Michigan, MI
Background/Purpose: Non-pharmacological fatigue management interventions in systemic sclerosis (SSc) are limited, despite people with SSc reporting that fatigue is inadequately addressed with clinical care. We…
Abstract Number: 1500 • ACR Convergence 2024
Work-Related Disability and Function in Systemic Lupus Erythematosus (SLE): Outcomes of an Exploratory Study from Different Canadian Centres
Behdin Nowrouzi-Kia¹, J. Antonio Avina-Zubieta², Mary Fox³, William Shaw⁴, Maggie Ho⁵, Qixuan Li⁵, Catherine Ivory⁶, Paul Fortin⁷, Stephanie Keeling⁸, Jennifer Reynolds⁹, Derek Haaland¹⁰, Janet Pope¹¹, Lily Lim¹², Patti Katz¹³, Murray Urowitz¹⁴, Laura Patricia Whittall Garcia⁵, Dafna Gladman¹⁵ and Zahi Touma¹, ¹University of Toronto, Toronto, ON, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³York University, Toronto, ON, Canada, ⁴University of Connecticut, School of Medicine, Farmington, CT, ⁵University Health Network, Toronto, ON, Canada, ⁶The Ottawa Hospital, Ottawa, ON, Canada, ⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁸University of Alberta, Edmonton, AB, Canada, ⁹UBC, North Vancouver, BC, Canada, ¹⁰The Waterside Clinic, Oro Medonte, ON, Canada, ¹¹University of Western Ontario, London, ON, Canada, ¹²University of Manitoba, Winnipeg, MB, Canada, ¹³UCSF, San Rafael, CA, ¹⁴Self employed, Toronto, ON, Canada, ¹⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) has a significant and long-lasting impact on work outcomes, is a source of long-lasting work disability, and presents challenges with…
Abstract Number: 2152 • ACR Convergence 2024
Factors Associated with Health-related Quality of Life in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – a Cross Sectional Analysis from the SAPHO-CNO Study
Aleksander Lenert¹, Helena Abodeely¹, Karmela Kim Chan², Sandy Hong³, Arundathi Jayatilleke⁴, Courtney Kremer⁵, Emma Leisinger¹, Petar Lenert⁶, Melissa Oliver⁷, T. Shawn Sato⁸, Melanie Smith², Thomason Jenna⁹, Yongdong (Dan) Zhao¹⁰, Jonathan Templin¹, Robyn Domsic¹¹, Mary Vaughan-Sarrazin¹, Daniel Solomon¹² and Polly Ferguson¹³, ¹University of Iowa, Iowa City, IA, ²Hospital For Special Surgery, New York, NY, ³University of Iowa Stead Family Children's Hospital, Iowa City, IA, ⁴Temple University, Philadelphia, PA, ⁵University of Iowa Stead Family Children's Hospital, Solon, Iowa, IA, ⁶University of Iowa Hospitals and Clinics, Iowa City, IA, ⁷Indiana University, Indianapolis, IN, ⁸University of Iowa, Iowa City, ⁹University of Washington, Division of Rheumatology, Seattle, WA, ¹⁰University of Washington, Redmond, WA, ¹¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹²Brigham and Women's Hospital, Newton, MA, ¹³University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: Health-related quality of life (HRQOL) is decreased in individuals with chronic rheumatic diseases (CRD) yet remains undefined in adults with SAPHO syndrome and chronic…
Abstract Number: 2241 • ACR Convergence 2024
Associations Between Disease Activity, Physical Function and Anti-rheumatic Medications with All-cause Mortality in Rheumatoid Arthritis (RA): Data from a Canadian RA Registry
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Bindee Kuriya³, Sibel Aydin⁴, Ed Keystone⁵, Janet Pope⁶ and Claire Bombardier⁷, and OBRI investigators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³University of Toronto - Toronto, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁶University of Western Ontario, London, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of hospitalizations and mortality due to RA itself, associated comorbidities, and treatment-related complications. The purpose…
Abstract Number: PP13 • ACR Convergence 2024
Bridging the Gap from Pediatric to Adult Rheumatology Care
Natasha Trehan, University of Ottawa, Take a Pain Check Foundation, Markham, ON, Canada
Background/Purpose: When I was 13, life took an unexpected turn with a diagnosis of Juvenile Idiopathic Arthritis (JIA). Overnight, my world transformed into a cycle…
Abstract Number: 0548 • ACR Convergence 2024
Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis
David Kiefer¹, Juergen Braun², Uta Kiltz³, Niklas Kolle¹, Lucia Schneider¹, Ioana Andreica⁴, Bjoern Buehring⁵, Philipp Sewerin⁶, Imke Redeker⁷, Styliani Tsiami⁸, Susanne Herbold⁹ and Xenofon Baraliakos⁸, ¹Ruhr-Universität Bochum; Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁵Bergisches Rheuma-Zentrum Wuppertal; Ruhr-Universität Bochum, Wuppertal, Germany, ⁶Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Ruhr Universität Bochum, Bochum, Germany, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Herne, Germany
Background/Purpose: Kinesiophobia, defined as the fear of movement, poses a significant barrier to effective rehabilitation, functional recovery, and adequate physical activity. To investigate the impact…
Abstract Number: 0682 • ACR Convergence 2024
Results from Outcomes Selection and Development of a Patient-reported Outcome Measure for a Combined Response Index for Limited Cutaneous SSc: The CRISTAL Project
Alain Lescoat¹, Yen Chen², Susan Murphy³, Nadia Vann², Neda Kortam², Rosemary Gedert², Sue Farrington⁴, Yannick Allanore⁵, David Cella⁶, Lorinda Chung⁷, Philip Clements⁸, Christopher Denton⁹, Francesco Del Galdo¹⁰, Oliver Distler¹¹, Monique Hinchcliff¹², Michael Hughes¹³, Laura Hummers¹⁴, John Pauling¹⁵, Janet Pope¹⁶, Virginia Steen¹⁷, John Varga², Peter Merkel¹⁸, Maya H. Buch¹⁹ and Dinesh Khanna², and all CRISTAL collaborators, ¹CHU Rennes - University Rennes 1, Rennes, France, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Plymouth, MI, ⁴Scleroderma & Raynaud UK, London, United Kingdom, ⁵Université Paris Cité, Paris, France, ⁶Northwestern University, Chicago, IL, ⁷Stanford University, Woodside, CA, ⁸United States, Los Angeles, CA, ⁹University College London, Northwood, United Kingdom, ¹⁰University of Leeds, Leeds, United Kingdom, ¹¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ¹²Yale School of Medicine, Westport, CT, ¹³Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ¹⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ¹⁵North Bristol NHS Trust, Bristol, United Kingdom, ¹⁶University of Western Ontario, London, ON, Canada, ¹⁷Georgetown University School of Medicine, Washington, DC, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) is the most frequent subset of scleroderma, yet there is a paucity of outcome measures available to assess symptoms…
Abstract Number: 1237 • ACR Convergence 2024
The Art of Choosing Together: Unveiling the Patient’s Perspective in Rheumatology
ADRIANA VANEGAS¹, Guillermo Quiceno², Luis Lira³, Gina Ochoa⁴, Álvaro Arbeláez-Cortés⁵, Mauricio Restrepo-Escobar⁶ and Virginia Pascual Ramos⁷, ¹HOSPITAL SAN VICENTE FUNDACION - UNIVERSIDAD DE ANTIOQUIA - Asociación Colombiana de Reumatología (ASOREUMA), MEDELLIN, Colombia, ²University of Tennessee Graduate School of Medicine, Dallas, TX, ³Sociedad Chilena de Reumatología, Santiago, Chile, ⁴Fundación LICAR, Barranquilla, Colombia, ⁵Clínica IMBANACO, Cali, Colombia, ⁶Universidad de Antioquia, Retiro, Colombia, ⁷Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico
Background/Purpose: Scientific evidence supports that shared decision-making (SDM) can improve adherence to treatment, patient satisfaction, quality of life, clinical outcomes, and healthcare costs. However, challenges…
Abstract Number: 1324 • ACR Convergence 2024
Rheumatoid Arthritis Associated Interstitial Lung Disease – Patient Perceptions and Recommendations
Shirish Dubey¹, Abhinav Peddasomayajula², Damodar Makkuni³, Anupama Nandagudi⁴, Win Win Maw⁵ and Gouri M Koduri⁶, ¹Oxford University Hospitals NHS FT, Oxford, United Kingdom, ²Mid and South Essex NHS Foundation Trust, Southend, England, United Kingdom, ³James Paget University Hospital NSH FT, Great Yarmouth, United Kingdom, ⁴MSEFT, Basildon, United Kingdom, ⁵Mid and South Essex NHS Foundation Trust, Chelmsford, England, United Kingdom, ⁶Southend Univeristy Hospitals NHS Trust, Essex, United Kingdom
Background/Purpose: Interstitial lung disease (ILD) is one of the complications of rheumatoid arthritis (RA) and has significant impact on morbidity and mortality. RA significantly reduces…
Abstract Number: 1555 • ACR Convergence 2024
Sustained Functional Assessment of Chronic Illness Therapy–Fatigue Response in Patients with SLE Receiving Anifrolumab Alongside Standard Therapy
Vibeke Strand¹, Kenneth Kalunian², Ian Bruce³, Caroline Seo⁴, Kai Wai Lee⁵, Jacob Knagenhjelm⁶ and Catharina Lindholm⁶, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of California San Diego, La Jolla, CA, ³Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁴BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, ⁵Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Fatigue is highly prevalent and severely affects health-related quality of life (HRQoL) in patients with SLE.1,2 We previously demonstrated that, compared with placebo, a…
Abstract Number: 2153 • ACR Convergence 2024
Construct Validity of the IDEOM Musculoskeletal Questionnaire (IDEOM MSK-Q) Using Data from the Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Lourdes Perez Chada¹, Ruogu Li², vivi feathers², Kumiko Schnock², Helen Early², Grace Carter², Neda Shahriari², Arianna Zhang², Jing Cui³, Michael Weinblatt⁴, Nancy Shadick², Alice Gottlieb⁵ and Joseph Merola⁶, ¹Harvard Medical School, Wayland, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ⁶UT Southwestern Medical Center, Newton, MA
Background/Purpose: Patients with psoriasis often present with musculoskeletal (MSK) symptoms, yet validated instruments to measure MSK symptoms in this population are limited. The IDEOM MSK-Q…
Abstract Number: 2265 • ACR Convergence 2024
Patient’s Global Assessment of Disease Activity Is the Most Relevant Factor for Near-Miss of Boolean 2.0 Remission in Patients with Rheumatoid Arthritis: Post Hoc Analysis from the Observational UPwArds Study
Torsten Witte¹, Uta Kiltz², Florian Haas³, Elke Riechers⁴, Ulrich Prothmann⁵, Daniela Adolf⁶, Alexander Rössler⁷, Kirsten Famulla⁸, Konrad Götz⁷ and Klaus Krüger⁹, ¹Dept of Immunology and Rheumatology, Hannover, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ³Internistisch-Rheumatologische Facharztpraxis, Rheumatology, Tübingen, Germany, ⁴Hannover Medical School, Department for Rheumatology and Immunology, Herne, Germany, ⁵Knappschaftsklinikum Saar GmbH, Püttlingen, Germany, ⁶StatConsult GmbH, Statistics, Magdeburg, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Immunology, Wiesbaden, Germany, ⁸AbbVie Deutschland GmbH & Co. KG, Immunology, North Chicago, ⁹Rheumatologisches Praxiszentrum, Munich, Germany, München, Germany
Background/Purpose: Patient’s Global Assessment of disease activity (PtGA) was found to be the most relevant limiting factor for achieving Boolean 1.0 remission in patients with…
Abstract Number: 0171 • ACR Convergence 2024
Associations Between Discrimination Experiences and Patient-Reported Outcomes Among Asian Individuals with Systemic Lupus Erythematosus (SLE)
Patti Katz¹, JoonSuk Park², Kamil Barbour³, Kurt Greenlund³, Maria Dall'Era⁴ and Jinoos Yazdany², ¹UCSF, San Rafael, CA, ²University of California San Francisco, San Francisco, CA, ³CDC, Alpharetta, GA, ⁴UCSF, Corte Madera, CA
Background/Purpose: Discrimination experiences have been linked to poor outcomes among Black individuals with SLE.1 Among Asian adults in the general US population, discrimination has been…
Abstract Number: 0560 • ACR Convergence 2024
Association Between a Self-Report Screening Tool for Sarcopenia (SARC-F) and Disease Activity, Muscle Strength and Muscle Power Measures, Patient-Reported Outcomes and Body Composition in Patients with Spondyloarthritides
Iuliia Kononenko¹, Marius Bedei², Bjoern Buehring³, Xenofon Baraliakos⁴ and Uta Kiltz⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany, Bochum, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany, Herne, Germany, ³Bergisches Rheuma-Zentrum, Wuppertal, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany
Background/Purpose: The SARC-F is a self-report screening tool for sarcopenia (Sar) used to identify individuals at risk for poor functional outcomes [1]. The aim of this study was…
Abstract Number: 0702 • ACR Convergence 2024
AISA 021, a Novel Calcium Channel Antagonist in Development for Raynaud’s & Systemic Sclerosis, Has Antagonistic Activity at Sodium Channel Targets for Pain Relief and Treats Scleroderma Pain Better Than Current Calcium Channel Blockers in a Phase 2A Study
Andrew Sternlicht¹ and Meredith Todd², ¹Tufts University Medical Center and Aisa Pharma, Inc., Boston, MA, ²Aisa Pharma Pty Ltd., East Lindfield, New South Wales, Australia
Background/Purpose: Improved treatments for Raynaud's phenomenon in Systemic Sclerosis (SSc) are needed. A novel oral calcium channel blocker (cilnidipine), with N-type channel antagonism is being…

« Previous Page
1
…
4
5
6
7
8
…
43
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].